Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma-Reference-Cited by-同舟云学术

Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma

Published:2020-11-28 Issue:1 Volume:1 Page:
ISSN:2690-442X
Container-title:Skin Health and Disease
language:en
Short-container-title:Skin Health and Disease

Author:

Ramirez‐Fort M. K.¹²³^ORCID,Meier‐Schiesser B.⁴,Lachance K.⁵,Mahase S. S.⁶,Church C. D.⁵,Niaz M. J.²^ORCID,Liu H.²,Navarro V.²,Nikolopoulou A.⁷,Kazakov D. V.⁴⁸,Contassot E.⁴,Nguyen D. P.²,Sach J.⁸,Hadravsky L.⁸,Sheng Y.⁹,Tagawa S. T.²¹⁰,Wu X.⁹¹¹,Lange C. S.¹³,French L. E.¹²,Nghiem P. T.⁵,Bander N. H.²

Affiliation:

1. Department of Life Sciences BioFort® Guaynabo Puerto Rico USA

2. Department of Urology Weill Cornell Medicine New York New York USA

3. Department of Radiation Oncology SUNY Downstate Health Sciences University Brooklyn New York USA

4. Department of Dermatology University Hospital of Zürich Zürich Switzerland

5. Department of Dermatology University of Washington Seattle Washington USA

6. Department of Radiation Oncology Weill Cornell Medicine New York New York USA

7. Department of Radiology Weill Cornell Medicine New York New York USA

8. Sikl's Department of Pathology Medical Faculty in Pilsen Charles University in Prague Pilsen Czech Republic

9. Shanghai Proton and Heavy Ion Center Shanghai China

10. Department of Medicine Weill Cornell Medicine New York New York USA

11. Innovative Cancer Institute Miami Florida USA